ABSTRACT
Emerging pollutants have been the subject of worldwide study because their continuous entry into the environment presents a risk to ecosystems and human health. Advanced oxidation processes show promise for eliminating or reducing the concentrations of emerging pollutants in water. This study aimed to investigate the treatment of aqueous systems containing the synthetic hormone 17α-ethinylestradiol. An innovative method for persulfate activation catalysed by iron-modified diatomite (heterogeneous system) was compared to conventional homogeneous activation methods (iron activation, alkaline activation, and heat activation). Iron-modified diatomite was more efficient in activating persulfate than traditional processes, achieving 98% of pollutant removal. Experimental results indicated that the catalyst can be reused without loss of removal efficiency, with potential environmental and economic benefits.
Subject(s)
Iron , Water Pollutants, Chemical , Diatomaceous Earth , Ecosystem , Ethinyl Estradiol , Humans , Oxidation-Reduction , Sulfates , Water , Water Pollutants, Chemical/analysisABSTRACT
BACKGROUND: A decline of protective antibody titers after MCC vaccine has been demonstrated in healthy children, this may be an issue of concern for risk groups. The aim of this study was to evaluate the persistence of bactericidal antibodies after MCC vaccine in sickle cell disease (SCD) patients. The type of vaccine used and booster response were also analyzed. METHODS: SCD patients (n=141) previously immunized with MCC vaccines had blood drawn 2-8 years after the last priming dose. They were distributed according to age at primary immunization into groups: <2 years and 2-13 years and evaluated by years since vaccination (2-3, 4-5 and 6-8). Serum bactericidal antibodies with baby rabbit complement (rSBA) and serogroup C-specific IgG concentrations were measured. The correlate of protection was rSBA titer ⩾8. Subjects with rSBA <8 received a booster dose and antibody levels re-evaluated after 4-6 weeks. RESULTS: For children primed under 2years of age rSBA titer ⩾8 was demonstrated in 53.3%, 21.7% and 35.0%, 2-3, 4-5, 6-8years, respectively, after vaccination, compared with 70.0%, 45.0% and 53.5%, respectively, for individuals primed at ages 2-13years. rSBA median titers and IgG median levels were higher in the older group. Six to eight years after vaccination the percentage of patients with rSBA titers ⩾8 was significantly higher in the group primed with MCC-TT (78.5%) compared with those primed with MCC-CRM197 [Menjugate® (33.3%) or Meningitec® (35.7%)] (p=0.033). After a booster, 98% achieved rSBA titer ⩾8. CONCLUSION: Immunity to meningococcal serogroup C in SCD children declines rapidly after vaccination and is dependent on the age at priming. Booster doses are needed to maintain protection in SCD patients. Persistence of antibodies seems to be longer in individuals primed with MCC-TT vaccine comparing to those immunized with MCC-CRM197.
Subject(s)
Anemia, Sickle Cell/immunology , Antibodies, Bacterial/blood , Meningococcal Infections/immunology , Meningococcal Vaccines/immunology , Neisseria meningitidis, Serogroup C/immunology , Vaccines, Conjugate/immunology , Adolescent , Child , Child, Preschool , Female , Humans , Immunization, Secondary , Male , Meningococcal Infections/epidemiology , Meningococcal Infections/prevention & control , Serum Bactericidal Antibody Assay , Time FactorsABSTRACT
The immunogenicity and tolerability of virosome and of split influenza vaccines in patients with sickle cell anemia (SS) were evaluated. Ninety SS patients from 8 to 34 years old were randomly assigned to receive either virosome (n=43) or split vaccine (n=47). Two blood samples were collected, one before and one 4-6 weeks after vaccination. Antibodies against viral strains (2006) A/New Caledonia (H1N1), A/California (H3N2), B/Malaysia were determined using the hemagglutinin inhibition test. Post-vaccine reactions were recorded over 7 days. Seroconversion rates for H1N1, H3N2 and B were 65.1%, 60.4% and 83.7% for virosome vaccine, and 68.0%, 61.7% and 68.0% for split vaccine. Seroprotection rates for H1N1, H3N2 e B were 100%, 97.6% and 69.7% for virosome, and 97.8%, 97.8% and 76.6% for split vaccine. No severe adverse reactions were recorded. Virosome and split vaccines in patients with sickle cell anemia were equally immunogenic, with high seroconversion and seroprotection rates. Both vaccines were well tolerated.